Schizophrenia News and Research RSS Feed - Schizophrenia News and Research

Schizophrenia is a chronic debilitating disorder which affects more than two million Americans, and millions more worldwide. While significant progress has been made in understanding the disease and developing treatments, there remains a significant unmet medical need. More than 50% of patients switch their medication in a given year due to either poor response or the experience of adverse events.
Accumulated environmental risks have substantial impact on schizophrenia

Accumulated environmental risks have substantial impact on schizophrenia

Accumulation of environmental risk factors has a “huge” effect on age at schizophrenia onset, German researchers report. [More]
Paternal age increases schizophrenia risk independently of IQ

Paternal age increases schizophrenia risk independently of IQ

Being born to an older father increases the risk of developing a schizophrenia spectrum disorder in adulthood but has no effect on premorbid IQ, say researchers from Denmark. [More]
Physical health management below par in schizophrenia patients

Physical health management below par in schizophrenia patients

The diagnosis and treatment of physical ailments in patients with schizophrenia falls below acceptable standards, shows a national audit of patients in England and Wales. [More]
Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. [More]
UCSD researchers validate EEG test to study, treat schizophrenia

UCSD researchers validate EEG test to study, treat schizophrenia

Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options. [More]
Teen binge drinking effects may last a lifetime, suggests UMass Amherst study

Teen binge drinking effects may last a lifetime, suggests UMass Amherst study

Binge drinking can have lasting effects on brain pathways that are still developing during adolescence, say neuroscience researcher Heather N. Richardson and her colleagues at the University of Massachusetts Amherst and Louisiana State University. [More]
Study finds that mental health disorders double heart disease, stroke risks

Study finds that mental health disorders double heart disease, stroke risks

People facing mental health challenges are significantly more likely to have heart disease or stroke, according to a study presented today at the Canadian Cardiovascular Congress. [More]
Dietary cocoa flavanols can reverse age-related memory decline in healthy older adults

Dietary cocoa flavanols can reverse age-related memory decline in healthy older adults

Dietary cocoa flavanols—naturally occurring bioactives found in cocoa—reversed age-related memory decline in healthy older adults, according to a study led by Columbia University Medical Center scientists. [More]
Engineered cells reveal changes associated with learning, memory and reward

Engineered cells reveal changes associated with learning, memory and reward

Scientists have created cells with fluorescent dyes that change color in response to specific neurochemicals. By implanting these cells into living mammalian brains, they have shown how neurochemical signaling changes as a food reward drives learning, they report in Nature Methods online October 26. [More]
Genetics underpin bullying victimisation influence on paranoia

Genetics underpin bullying victimisation influence on paranoia

Bullying victimisation in childhood may indicate genetic risk for later psychosis, rather than being an environmental trigger, say UK researchers. [More]

Changing placebo response dilutes antipsychotic trial power

Factors including patients’ expectations may underlie an increased placebo response in antipsychotic randomised controlled trials published since 1960, say researchers. [More]
Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros provides update on OMS824 for treatment of schizophrenia, Huntington's disease

Omeros Corporation today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. [More]
Fatty fish intake appears to increase antidepressant response rates

Fatty fish intake appears to increase antidepressant response rates

Up to half of patients who suffer from depression (Major Depressive Disorder, or MDD) do not respond to treatment with SSRIs (Selective Serotonin Reuptake Inhibitors). Now a group of Dutch researchers have carried out a study which shows that increasing fatty fish intake appears to increase the response rate in patients who do not respond to antidepressants. [More]
Aspirin can improve efficacy of schizophrenia treatments

Aspirin can improve efficacy of schizophrenia treatments

A new study shows that some anti-inflammatory medicines, such as aspirin, estrogen, and Fluimucil, can improve the efficacy of existing schizophrenia treatments. This work is being presented at the European College of Neuropsychopharmacology conference in Berlin. [More]
People with severe mental illness use YouTube to provide, receive peer support

People with severe mental illness use YouTube to provide, receive peer support

People with severe mental illness such as schizophrenia, schizoaffective disorder or bipolar disorder use a popular social media website like YouTube to provide and receive naturally occurring peer support, Dartmouth researchers report in the journal PLOS ONE. [More]
Genome Canada awards $6M grant to CAMH and Assurex Health

Genome Canada awards $6M grant to CAMH and Assurex Health

Assurex Health and Canada's Centre for Addiction and Mental Health (CAMH) today announced they have received a $6 million grant from Genome Canada, an agency of the Canadian government, to study the benefits of genetic testing to guide medication decisions for patients with depression or schizophrenia. [More]
Study: More interventions needed for people with severe mental illnesses in criminal justice system

Study: More interventions needed for people with severe mental illnesses in criminal justice system

Responding to the large number of people with serious mental illnesses in the criminal justice system will require more than mental health services, according to a new report. [More]
Research on zebrafish helps identify cause of unknown genetic disorder

Research on zebrafish helps identify cause of unknown genetic disorder

Research in zebrafish has helped identify the cause of an unknown genetic disorder affecting a boy and two of his uncles, scientists report in an article published October 14 in the journal GENETICS. [More]
Cardiometabolic health intervention urged for schizophrenia patients

Cardiometabolic health intervention urged for schizophrenia patients

Research shows high cardiometabolic risk, particularly increased dyslipidaemia and smoking, but little related medical treatment in patients with first-episode schizophrenia. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]